Literature DB >> 24379123

Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis.

Xin Huang1, Yaping Chen, Chun-Shiang Chung, Zhenglong Yuan, Sean F Monaghan, Fei Wang, Alfred Ayala.   

Abstract

Identifying relevant mediators responsible for the pathogenesis during sepsis may lead to finding novel diagnostic and therapeutic targets. Recent studies indicate programmed cell death receptor (PD)-1 plays a significant role in the development of immune suppression associated with sepsis. In this study, we determine whether B7-H1, the primary ligand of PD-1, contributes to the pathogenesis of sepsis. We report that B7-H1 is upregulated extensively on various immune cells during sepsis and B7-H1 gene deficiency protects mice from the lethality of sepsis. In terms of the histological development of multiple organ damage and inflammatory cytokine levels in circulation or at infectious site, B7-H1-deficient mice showed a remarkable reduction in these indices when compared with wild-type mice. However, B7-H1 gene-deficient mice did not exhibit a lower bacterial burden when compared with wild-type mice, although they recruited more macrophages and neutrophils into infectious site. In addition, we found that, during sepsis, whereas there were no marked differences affecting ex vivo macrophage cytokine productive capacity between PD-1 and B7-H1 gene-deficient mice, preservation of ex vivo macrophage phagocytic function was only seen in septic PD-1 knockout mouse cells. Finally, higher percentage B7-H1(+) neutrophils in peripheral blood correlated not only with higher levels of pro- and anti-inflammatory cytokines/chemokines (CCL2, IL-6, CXCL2, KC, TNF-α, and IL-10), but with lethal outcome as well. Together, these results indicate B7-H1 contributes to septic morbidity in fashion distinct from PD-1 and suggest B7-H1 expression on neutrophils could be used as a biomarker of septic severity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24379123      PMCID: PMC3947010          DOI: 10.4049/jimmunol.1302252

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans.

Authors:  R S Hotchkiss; K W Tinsley; P E Swanson; R E Schmieg; J J Hui; K C Chang; D F Osborne; B D Freeman; J P Cobb; T G Buchman; I E Karl
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

Review 2.  Predictors of survival in sepsis: what is the best inflammatory marker to measure?

Authors:  Christoph Lichtenstern; Thorsten Brenner; Hubert J Bardenheuer; Markus A Weigand
Journal:  Curr Opin Infect Dis       Date:  2012-06       Impact factor: 4.915

3.  The epidemiology of sepsis in the United States from 1979 through 2000.

Authors:  Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

4.  Expression of programmed death 1 ligands by murine T cells and APC.

Authors:  Tomohide Yamazaki; Hisaya Akiba; Hideyuki Iwai; Hironori Matsuda; Mami Aoki; Yuka Tanno; Tahiro Shin; Haruo Tsuchiya; Drew M Pardoll; Ko Okumura; Miyuki Azuma; Hideo Yagita
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

Review 5.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

6.  Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis.

Authors:  Craig M Coopersmith; Paul E Stromberg; W Michael Dunne; Christopher G Davis; Daniel M Amiot; Timothy G Buchman; Irene E Karl; Richard S Hotchkiss
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

Review 7.  The inflammatory response in sepsis.

Authors:  Markus Bosmann; Peter A Ward
Journal:  Trends Immunol       Date:  2012-10-02       Impact factor: 16.687

Review 8.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

Review 9.  The immunopathogenesis of sepsis.

Authors:  Jonathan Cohen
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

10.  Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1.

Authors:  Noelle A Hutchins; Fei Wang; Yvonne Wang; Chun-Shiang Chung; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2013-06-13       Impact factor: 4.962

View more
  31 in total

1.  A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction.

Authors:  Anne-Lise Rossi; Marilyn Le; Chun-Shiang Chung; Yaping Chen; Eleanor A Fallon; Andres Matoso; Shumin Xu; Tristen T Chun; Craig P Erickson; Alfred Ayala
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-15       Impact factor: 4.052

Review 2.  Emerging infection and sepsis biomarkers: will they change current therapies?

Authors:  Lauren Jacobs; Hector R Wong
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08-17       Impact factor: 5.091

Review 3.  Role of cellular events in the pathophysiology of sepsis.

Authors:  Chandra Bhan; Pankaj Dipankar; Papiya Chakraborty; Pranita P Sarangi
Journal:  Inflamm Res       Date:  2016-07-08       Impact factor: 4.575

Review 4.  Advances in the understanding and treatment of sepsis-induced immunosuppression.

Authors:  Fabienne Venet; Guillaume Monneret
Journal:  Nat Rev Nephrol       Date:  2017-12-11       Impact factor: 28.314

Review 5.  The new normal: immunomodulatory agents against sepsis immune suppression.

Authors:  Noelle A Hutchins; Jacqueline Unsinger; Richard S Hotchkiss; Alfred Ayala
Journal:  Trends Mol Med       Date:  2014-01-30       Impact factor: 11.951

Review 6.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

Review 7.  Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.

Authors:  Naeem K Patil; Julia K Bohannon; Edward R Sherwood
Journal:  Pharmacol Res       Date:  2016-07-25       Impact factor: 7.658

8.  Flt3 Ligand Treatment Attenuates T Cell Dysfunction and Improves Survival in a Murine Model of Burn Wound Sepsis.

Authors:  Naeem K Patil; Julia K Bohannon; Liming Luan; Yin Guo; Benjamin Fensterheim; Antonio Hernandez; Jingbin Wang; Edward R Sherwood
Journal:  Shock       Date:  2017-01       Impact factor: 3.454

9.  Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.

Authors:  Andriani C Patera; Anne M Drewry; Katherine Chang; Evan R Beiter; Dale Osborne; Richard S Hotchkiss
Journal:  J Leukoc Biol       Date:  2016-09-26       Impact factor: 4.962

10.  Programmed cell death receptor ligand 1 modulates the regulatory T cells' capacity to repress shock/sepsis-induced indirect acute lung injury by recruiting phosphatase SRC homology region 2 domain-containing phosphatase 1.

Authors:  Lunxian Tang; Jianwen Bai; Chun-Shiang Chung; Joanne Lomas-Neira; Yaping Chen; Xin Huang; Alfred Ayala
Journal:  Shock       Date:  2015-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.